Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

Leukemia Microenvironment and Pathologic Hypoxia: Sensitivity to Hypoxia-Activated Cytotoxin TH-302

Juliana M Benito, PhD, Volgin Y Andrei, Ye Chen, PhD, Lu Hongbo, Yuexi Shi, Teresa McQueen, Patrick A Zweidler-McKay, MD, PhD, Damian R Handisides, Charles Hart, Michael Andreeff, MD, PhD, Marina Konopleva, M.D., Ph.D.

Blood (2012) 120 (21): 1523.

https://doi.org/10.1182/blood.V120.21.1523.1523

Published: 2012

Journal Articles

Phase1/2 Single Arm Study of Rigosertib (ON 01910.Na) in Patients (Pts) with Relapsed or Refractory Acute Leukemia or Transformed Myeloproliferative Neoplasms

Lakshmikanth Katragadda, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Tapan M. Kadia, M.D., Alessandra Ferrajoli, M.D., Elias J. Jabbour, MD, Alfonso Quintas-Cardama, MD, Marina Konopleva, M.D., Ph.D., Manoj Maniar, PhD, Francois Wilhelm, MD, PhD., Farhad Ravandi, MD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 3606.

https://doi.org/10.1182/blood.V120.21.3606.3606

Published: 2012

Journal Articles

Targeting Hypoxia and AKR1C3 with PR104 in Patients with Acute Leukemia

Juliana M Benito, PhD, Hongbo Lu, William R Wilson, PhD, Teresa J Melink, NP, MSN, Jennie Bretz, Sergej Konoplev, MD, PhD, Elihu H. Estey, MD, Hagop M. Kantarjian, MD, John C Gutheil, MD, Michael Andreeff, MD, PhD, Marina Konopleva, M.D., Ph.D.

Blood (2012) 120 (21): 3615.

https://doi.org/10.1182/blood.V120.21.3615.3615

Published: 2012

Journal Articles

Connective Tissue Growth Factor (CTGF) Regulates Mesenchymal Stromal Cell De-Differentiation Into Adipocyte Progenitors and Facilitates Leukemic Cell Homing to Extra-Medullary Bone Marrow

Venkata Lokesh Battula, Ph.D., Ye Chen, Ph.D., Marina Konopleva, M.D., Ph.D., Michael Andreeff, M.D., Ph.D.

Blood (2011) 118 (21): 2391.

https://doi.org/10.1182/blood.V118.21.2391.2391

Published: 2011

Journal Articles

Phase I Study of the Combination of 5-Azacitidine Sequentially with High-Dose Lenalidomide in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

Guillermo Garcia-Manero, Naval G. Daver, MD, Gautam Borthakur, Marina Konopleva, M.D., Ph.D., Farhad Ravandi, MD, William G. Wierda, MD, PhD, Zeev Estrov, Stefan Faderl, MD, Tapan Kadia, Kristy Rey, MS, RN, Cora Cheung, RN, Hagop M. Kantarjian

Blood (2011) 118 (21): 2613.

https://doi.org/10.1182/blood.V118.21.2613.2613

Published: 2011

Journal Articles

Role of Connective Tissue Growth Factor (CTGF) in Survival and Chemosensitivity of Acute Lymphoblastic Leukemia

Hongbo Lu, MMSC, Venkata Lokesh Battula, Ph.D., Yuexi Shi, Richard B Lock, PhD, Suzanne Spong, Ph.D, Michael Andreeff, M.D., Ph.D., Marina Konopleva, M.D., Ph.D.

Blood (2011) 118 (21): 2593.

https://doi.org/10.1182/blood.V118.21.2593.2593

Published: 2011

Journal Articles

The PP2A Subunit B55α Suppresses Survival Signaling in Acute Myeloid Leukemia Cells

Peter P. Ruvolo, PhD, Vivian Ruvolo, Zhihong Zeng, YiHua Qui, MD, Liran Zhou, PhD, Kelly E Gallagher, Marina Konopleva, M.D., Ph.D., Steven M. Kornblau, MD, Michael Andreeff, M.D., Ph.D.

Blood (2011) 118 (21): 396.

https://doi.org/10.1182/blood.V118.21.396.396

Published: 2011

Journal Articles

Safety, Pharmacokinetics, and Efficacy of BP-100.1.01 (L-Grb-2 Antisense Oligonucleotide) in Patients with Refractory or Relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Myelodysplastic Syndrome (MDS),

Jorge E. Cortes, Guillermo Garcia-Manero, Farhad Ravandi, MBBS, Michael Andreef, MD, PhD, Gautam Borthakur, Elias Jabbour, Marina Konopleva, M.D., Ph.D., Susan o'Brien, Alfonso Quintas-Cardama, Srdan Verstovsek, MD, PhD, William G. Wierda, MD, PhD, Hagop M. Kantarjian

Blood (2011) 118 (21): 3639.

https://doi.org/10.1182/blood.V118.21.3639.3639

Published: 2011

Journal Articles

AR-67, a DNA Topo-Isomerase I Inhibitor, Demonstrates Acceptable Tolerability and Preliminary Activity in a Phase II Trial of Patients with Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML),

Naval Daver, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, Gautam Borthakur, Farhad Ravandi, MD, Tapan Kadia, Zeev Estrov, Marina Konopleva, M.D., Ph.D., Stefan Faderl, MD, Jorge E. Cortes

Blood (2011) 118 (21): 3820.

https://doi.org/10.1182/blood.V118.21.3820.3820

Published: 2011

Journal Articles

Improved Early Outcomes with T-Cell Replete (TCR) Compared with T-Cell Depleted (TCD) Haploidentical Stem Cell Transplantation (HaploSCT)

Stefan O Ciurea, MD, Rima M. Saliba, PhD, Ulas D. Bayraktar, MD, Susan Xie, Gabriela Rondon, MD, Simrit Parmar, M.D., Partow Kebriaei, MD, Nivia Montes, PA, Manish Sharma, MD, Marina Konopleva, M.D., Ph.D., Yago Nieto, MD, PhD, Muzaffar H. Qazilbash, MD, Amin M Alousi, MD, Borje S Andersson, MD, PhD, Chitra M Hosing, MD, Elizabeth J Shpall, MD, Issa F. Khouri, MD, Marcos de Lima, MD, Richard Champlin, MD

Blood (2011) 118 (21): 320.

https://doi.org/10.1182/blood.V118.21.320.320

Published: 2011

Journal Articles

Acquired Point Mutations of TKD Are Responsible for Sorafenib Resistance in FLT3-ITD Mutant AML,

Weiguo Zhang, M.D., Ph.D., Marina Konopleva, M.D., Ph.D., Rodrigo O Jacamo, Ph.D., Gautam Borthakur, M.D, Wenjing Chen, Jorge E. Cortes, Farhad Ravandi, MD, Michael Andreeff, M.D., Ph.D.

Blood (2011) 118 (21): 3505.

https://doi.org/10.1182/blood.V118.21.3505.3505

Published: 2011

Journal Articles

Twice Daily Fludarabine and Cytarabine Combination Is Effective in Patients with Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndromes, and Blast Phase Chronic Myeloid Leukemia,

Naval Daver, MD, Hagop M. Kantarjian, Guillermo Garcia-Manero, Jorge E. Cortes, Farhad Ravandi, MD, William Plunkett, PhD, Varsha Gandhi, PhD, Stefan Faderl, MD, Susan o'Brien, Gautam Borthakur, Tapan Kadia, Jan A. Burger, MD, PhD, Marina Konopleva, M.D., Ph.D., Mark Brandt, BS, Xuelin Huang, PhD, Elias Jabbour

Blood (2011) 118 (21): 3629.

https://doi.org/10.1182/blood.V118.21.3629.3629

Published: 2011

Journal Articles

Final Report of a Phase II Trial of Vorinostat with Idarubicin and Cytarabine for Patients with Newly Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Guillermo Garcia-Manero, Francesco Paolo Tambaro, MD, PhD, Nebiyou Bekele, Hui Yang, Farhad Ravandi, MD, Elias Jabbour, Gautam Borthakur, Tapan Kadia, Marina Konopleva, M.D., Ph.D., Stefan Faderl, MD, Jorge E. Cortes, Mark Brandt, BS, Yumin Hu, PhD, Deborah McCue, Willie Mae Newsome, RN, Sherry Pierce, RN, BS, Marcos DeLima, MD, Hagop M. Kantarjian

Blood (2011) 118 (21): 763.

https://doi.org/10.1182/blood.V118.21.763.763

Published: 2011

Journal Articles

Human Extramedullary Bone and Bone Marrow in Mice: First In Vivo Model of a Genetically Controlled Hematopoietic Environment

Ye Chen, Ph.D., Rodrigo O Jacamo, Ph.D., Nicole A. Hofmann, Yue-xi Shi, PhD, Rui-yu Wang, PhD, Sergej Konoplev, MD, PhD, Dirk Strunk, MD, Marina Konopleva, M.D., Ph.D., Michael Andreeff, M.D., Ph.D.

Blood (2011) 118 (21): 1323.

https://doi.org/10.1182/blood.V118.21.1323.1323

Published: 2011

Journal Articles

Final Report of a Phase II Study of 5-Azacitidine and Vorinostat in Patients (pts) with Newly Diagnosed Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML) Not Eligible for Clinical Trials Because Poor Performance and Presence of Other Comorbidities

Guillermo Garcia-Manero, Elihu H Estey, MD, Elias Jabbour, Gautam Borthakur, Tapan Kadia, Kiran Naqvi, MD, Ross L Levine, MD, Zeev Estrov, Alfonso Quintas-Cardama, MD, Marina Konopleva, M.D., Ph.D., Stefan Faderl, MD, Maria Tanaka, MD, Hui Yang, Farhad Ravandi, MD, William G. Wierda, MD, PhD, Jorge E. Cortes, Patricia Ann Boone, Hagop M. Kantarjian

Blood (2011) 118 (21): 608.

https://doi.org/10.1182/blood.V118.21.608.608

Published: 2011

Journal Articles

Clinical Significance of Complete Cytogenetic Response (CCyR) and Major Molecular Response (MMR) Achieved with Different Treatment Modalities Used As Frontline Therapy In Chronic Myeloid Leukemia (CML) Chronic Phase (CP)

Mona Lisa Alattar, MD, Hagop M. Kantarjian, Elias Jabbour, Alfonso Quintas-Cardama, MD, Elizabeth M Burton, Gautam Borthakur, Srdan Verstovsek, MD, PhD, William G. Wierda, MD, PhD, Marina Konopleva, M.D., Ph.D., Jan A. Burger, MD, PhD, Susan O'Brien, MD, Jorge E. Cortes

Blood (2011) 118 (21): 745.

https://doi.org/10.1182/blood.V118.21.745.745

Published: 2011

Journal Articles

Outcome of Patients with Philadelphia Chromosome-Positive (Ph + ) Acute Lymphoblastic Leukemia (ALL) with Relapse After Tyrosine Kinase Inhibitor (TKI) Therapy

Hun Ju Lee, MD, Susan O'Brien, MD, Hagop M. Kantarjian, Farhad Ravandi, MD, Stefan Faderl, MD, Charles Koller, MD, Marina Konopleva, M.D., Ph.D., Srdan Verstovsek, MD, PhD, Tapan Kadia, Guillermo Garcia-Manero, Gautam Borthakur, William G. Wierda, MD, PhD, Jan A. Burger, MD, PhD, Deborah A. Thomas, MD, Jorge E. Cortes

Blood (2011) 118 (21): 1518.

https://doi.org/10.1182/blood.V118.21.1518.1518

Published: 2011

Journal Articles

Phase I/II Study of PR104, a Bioreductive Prodrug, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) Using Patient-Specific Adaptive Dose Selection

Marina Konopleva, M.D., Ph.D., Gautam Borthakur, Peter F Thall, PhD, Andrew Coveler, MD, Farhad Ravandi, MD, Elias Jabbour, Hoang Q Nguyen, PhD, Juliana M Benito, PhD, Yongchuan Gu, PhD, William R Wilson, PhD, Teresa J Melink, NP, MSN, Hagop M. Kantarjian, John C Gutheil, MD, Elihu H Estey, MD

Blood (2011) 118 (21): 1523.

https://doi.org/10.1182/blood.V118.21.1523.1523

Published: 2011

Journal Articles

Outcomes for Adult Lymphoblastic Leukemia (ALL) Are Mainly Influenced by Age and Status of Minimal Residual Disease (MRD) by Multiparameter Flow Cytometry (MFC) After Therapy with the Modified Hyper-CVAD (with or without Rituximab) Regimen

Blood (2011) 118 (21): 1524.

https://doi.org/10.1182/blood.V118.21.1524.1524

Published: 2011

Journal Articles

Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients Younger Than 61 Years with Newly Diagnosed Acute Myeloid Leukemia (AML)

Aziz Nazha, Farhad Ravandi, MD, Hagop M. Kantarjian, Guillermo Garcia-Manero, Elias Jabbour, Gautam Borthakur, Tapan Kadia, Marina Konopleva, M.D., Ph.D., Jorge E. Cortes, Alessandra Ferrajoli, MD, Steven M. Kornblau, Michael Andreeff, M.D., Ph.D., Min Du, Mark Brandt, BS, Stefan Faderl, MD

Blood (2011) 118 (21): 1550.

https://doi.org/10.1182/blood.V118.21.1550.1550

Published: 2011

NARROW

Leukemia Microenvironment and Pathologic Hypoxia: Sensitivity to Hypoxia-Activated Cytotoxin TH-302

Phase1/2 Single Arm Study of Rigosertib (ON 01910.Na) in Patients (Pts) with Relapsed or Refractory Acute Leukemia or Transformed Myeloproliferative Neoplasms

Targeting Hypoxia and AKR1C3 with PR104 in Patients with Acute Leukemia

Connective Tissue Growth Factor (CTGF) Regulates Mesenchymal Stromal Cell De-Differentiation Into Adipocyte Progenitors and Facilitates Leukemic Cell Homing to Extra-Medullary Bone Marrow

Phase I Study of the Combination of 5-Azacitidine Sequentially with High-Dose Lenalidomide in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

Role of Connective Tissue Growth Factor (CTGF) in Survival and Chemosensitivity of Acute Lymphoblastic Leukemia

The PP2A Subunit B55α Suppresses Survival Signaling in Acute Myeloid Leukemia Cells

Safety, Pharmacokinetics, and Efficacy of BP-100.1.01 (L-Grb-2 Antisense Oligonucleotide) in Patients with Refractory or Relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Myelodysplastic Syndrome (MDS),

AR-67, a DNA Topo-Isomerase I Inhibitor, Demonstrates Acceptable Tolerability and Preliminary Activity in a Phase II Trial of Patients with Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML),

Improved Early Outcomes with T-Cell Replete (TCR) Compared with T-Cell Depleted (TCD) Haploidentical Stem Cell Transplantation (HaploSCT)

Acquired Point Mutations of TKD Are Responsible for Sorafenib Resistance in FLT3-ITD Mutant AML,

Twice Daily Fludarabine and Cytarabine Combination Is Effective in Patients with Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndromes, and Blast Phase Chronic Myeloid Leukemia,

Final Report of a Phase II Trial of Vorinostat with Idarubicin and Cytarabine for Patients with Newly Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Human Extramedullary Bone and Bone Marrow in Mice: First In Vivo Model of a Genetically Controlled Hematopoietic Environment

Final Report of a Phase II Study of 5-Azacitidine and Vorinostat in Patients (pts) with Newly Diagnosed Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML) Not Eligible for Clinical Trials Because Poor Performance and Presence of Other Comorbidities

Clinical Significance of Complete Cytogenetic Response (CCyR) and Major Molecular Response (MMR) Achieved with Different Treatment Modalities Used As Frontline Therapy In Chronic Myeloid Leukemia (CML) Chronic Phase (CP)

Outcome of Patients with Philadelphia Chromosome-Positive (Ph + ) Acute Lymphoblastic Leukemia (ALL) with Relapse After Tyrosine Kinase Inhibitor (TKI) Therapy

Phase I/II Study of PR104, a Bioreductive Prodrug, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) Using Patient-Specific Adaptive Dose Selection

Outcomes for Adult Lymphoblastic Leukemia (ALL) Are Mainly Influenced by Age and Status of Minimal Residual Disease (MRD) by Multiparameter Flow Cytometry (MFC) After Therapy with the Modified Hyper-CVAD (with or without Rituximab) Regimen

Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients Younger Than 61 Years with Newly Diagnosed Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only